Kiora Pharmaceuticals (KPRX) Accumulated Expenses (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Accumulated Expenses came in at $2.0 million in Q1 2026, down 42.5% YoY from $3.5 million in Q1 2025, and down 15.85% on a QoQ basis from $2.4 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Accumulated Expenses (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Accumulated Expenses data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Accumulated Expenses fell 42.5% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 42.5% YoY) and the FY2025 annual result came in at $2.4 million, down 47.55% from the prior year.
- Accumulated Expenses declined to $2.0 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $4.6 million in Q4 2024 to a low of $550133.0 in Q3 2022.
- A 5-year average of $1.9 million and a median of $1.7 million in 2024 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 357.51% in 2022, down 60.4% in 2022.
- Tracing KPRX's Accumulated Expenses over 5 years: stood at $1.8 million in 2022, then declined by 24.8% to $1.4 million in 2023, then soared by 232.35% to $4.6 million in 2024, then slumped by 47.55% to $2.4 million in 2025, then decreased by 15.85% to $2.0 million in 2026.
- The last three Accumulated Expenses figures came in at $2.0 million (Q1 2026), $2.4 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.98 Mn |
| Mar 31, 2026 | 2.03 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | 2.54 Mn |
| Mar 31, 2025 | 3.52 Mn |
| Dec 31, 2024 | 4.59 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 550,133.00 |
| Jun 30, 2022 | 1.63 Mn |
| Mar 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | 1.33 Mn |
| Sep 30, 2021 | 1.39 Mn |